References
- Gandolfi S, Prada CP, Richardson PG. How I treat the young patient with multiple myeloma. Blood. 2018;132(11):1114–1124.
- Kazandjian D, Mo CC, Landgren O, et al. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020;191(5):692–703.
- Sehgal P, Biran N, Sahni G, et al. Incidence of hypotension in patients with multiple myeloma during high dose chemotherapy and autologous stem cell rescue. Blood. 2013;122(21):3324–3324.
- Biran N, Sehgal P, Sahni G, et al. Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy. Am J Hematol. 2015;90(6):E125–E127.
- Metzler M, Duerr S, Granata R, et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212–2219.
- Stratogianni A, Tosch M, Schlemmer H, et al. Bortezomib-induced severe autonomic neuropathy. Clin Auton Res. 2012;22(4):199–202.
- Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630–639.
- Suyani E, Aki Z, Yeğin ZA, et al. Bortezomib-associated severe orthostatic hypotension and hyponatremia. Turk J Hematol. 2012;29(3):301–302.
- San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11(1):51–61.
- Ahmed S, Chapman L, Desmond R, et al. Increased incidence of symptomatic postural hypotension in multiple myeloma patients treated with subcutaneous bortezomib. Clin Lymphoma Myeloma Leuk. 2015;15:E165.
- Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens. 2011;24(2):135–144.
- Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2006;114(7):630–636.
- Weiss A, Grossman E, Beloosesky Y, et al. Orthostatic hypotension in acute geriatric ward: is it a consistent finding? Arch Intern Med. 2002;162(20):2369–2374.
- International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
- Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol. 2013;31(22):2806–2809.
- Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):1091–1114.
- Chen HH, Li YD, Cheng PW, et al. Gabapentin reduces blood pressure and heart rate through the nucleus tractus solitarii. Acta Cardiol Sin. 2019;35(6):627–633.
- Doleman B, Sherwin M, Lund JN, et al. Gabapentin for the hemodynamic response to intubation: systematic review and meta-analysis. Can J Anaesth. 2016;63(9):1042–1058.
- Bala I, Bharti N, Ramesh NP. Effect of gabapentin pretreatment on the hemodynamic response to laryngoscopy and tracheal intubation in treated hypertensive patients. Acta Anaesthesiol Taiwan. 2015;53(3):95–98.
- Ayatollahi V, Mirshamsi P, Behdad S, et al. Effect of oral gabapentin on haemodynamic variables during microlaryngoscopic surgery. Anaesthesiol Intensive Ther. 2014;46(1):17–22.
- Strogatz DS, Keenan NL, Barnett EM, et al. Correlates of postural hypotension in a community sample of elderly blacks and whites. J Am Geriatr Soc. 1991;39(6):562–566.
- Lockwood JM, Wilkins BW, Halliwill JR. H1 receptor-mediated vasodilatation contributes to postexercise hypotension. J Physiol. 2005;563(2):633–642.
- Ziegler MG, Rizos DP. The causes of postural cardiovascular disorders. Hypertension. 2005;45(3):354–355.
- Kligman AM. Topical pharmacology and toxicology of dimethyl sulfoxide. 1. JAMA. 1965;193:796–804.
- Gad SE, Sullivan DW. Dimethyl sulfoxide (DMSO). In: Wexler P, editor. Encyclopedia of toxicology. 3rd ed. Oxford: Academic Press; 2014. p. 166–168.
- Aung AK, Corcoran SJ, Nagalingam V, et al. Prevalence, associations, and risk factors for orthostatic hypotension in medical, surgical, and trauma inpatients: an observational cohort study. Ochsner J. 2012;12(1):35–41.
- Vecchie A, Thomas G, Bressi E, et al. Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience. Cardiooncology. 2021;7(1):40.
- Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood. 2015;125(2):410–412.
- Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379–398.
- Kligman AM. Dimethyl sulfoxide. 2. JAMA. 1965;193:923–928.